Girault found that melanoma patients with high expression levels of PD‐1 and PD‐L1 treated with anti‐PD‐1 inhibitors experienced longer OS43; tumor mutational burden (TMB), which is another hotspot in the determination of predictive markers for immunotherapy, was found to be associated with the risk of tumor recurrence and the efficacy of oncology treatment.44, 45. Here, CD274 is linked to neoplasm.